Let’s face it, the U.S. government stinks when it comes to medical marijuana, and it seems hard to believe that pharmaceutical company lobbyists aren’t part of the problem.
Back in November BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) submitted an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) for injectable formulations of peramivir, the company’s influenza neuraminidase inhibitor.